Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.71 |
| ▸ | SYK | P43405 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626446 | 1.00 | NAAA (1.00) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL9785906 | 1.00 | NAAA (1.00) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL11212195 | 1.00 | NAAA (1.00) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL10883907 | 0.88 | NAAA (0.78) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL12919722 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL17774851 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL17774885 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL15887753 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL19077958 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK | |
| SCHEMBL26096811 | 0.85 | NAAA (0.74) | NAAAEGFRALOX5PTGS2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149530-B2 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8426466-B2 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20070269494-A1 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269494-A1 | Compositions and methods for enhancing active agent absorption | FABP2, SLC10A2, SI | NAAA 440/4885EGFR 2675/4885ALOX5 242/4885 |
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | FABP2, SLC10A2, SI | NAAA 440/4885EGFR 2675/4885ALOX5 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.